Tempus AI

TEM

Market cap $12.3B

Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care.

Healthcare leaders are partnering with Tempus AI to bolster their development pipelines. Tempus' sales are expanding at a rapid pace.

Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

TEM has surged 105% in a year on AI-driven growth, FDA clearances and improving margins, but GAAP losses still cloud the outlook.

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation's premier academic medical centers, today announced a multi-year strategic collaboration aimed at transforming cancer care through advanced molecular profiling and data-driven insights. The collaboration will support NYU Langone Health's Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center, a comprehensive, pan-cancer initiative to more.

Tempus AI stock remains in a bear market after crashing by 36% from its highest point in September last year. It has slumped to $66, with its market capitalization slumping from $17.8 billion in October to the current $12.1 billion.

CHICAGO--(BUSINESS WIRE)--Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing. Patients will benefit from a deeper understanding of their unique cancer, enabling clinicians to deploy tailored, effective treatments. “The collaboration with Tempus will su.

U.S. stock futures declined on Monday after a positive close on Friday. Futures of major benchmark indices were trading lower.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Full Year 2025 Select, Preliminary, Unaudited Financial Results Revenue of ~$1.27 billion, representing ~83% growth year-over-year, including ~30% organic growth (excluding Ambry) Diagnostics revenue of ~$955 million, representing ~111% growth ye.